Therapeutic or Preventive Procedure
Illumina and Tempus look beyond cancer in new AI-driven genomics deal
Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market
Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides
Cyprumed, Merck, biobucks, Peptides
Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives
Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%
Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack
Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte
Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test
Antibiotics, Probiotics, House mice, Immune response, Vaccines
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval
Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool
PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats